Page last updated: 2024-12-11

n-(1-(2,3-dioleyloxy)propyl)-n,n,n-trimethylammonium chloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium: cationic lipid; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6438350
SCHEMBL ID156278
MeSH IDM0152760

Synonyms (25)

Synonym
dotma
n-[1-(2,3-dioleyloxy)propyl]-n,n,n-trimethylammonium chloride
104162-48-3
trimethyl[2,3-(dioleyloxy)propyl]ammonium chloride
T1307
n-(1-(2,3-dioleyloxy)propyl)-n,n,n-trimethylammonium
n-(1-(2,3-dioleyloxy)propyl)-n,n,n-trimethylammonium chloride
1-propanaminium, n,n,n-trimethyl-2,3-bis(9-octadecenyloxy)-, chloride, (z,z)-
SCHEMBL156278
n-[1-(2,3-dioleyloxy) propyl]-n,n,n-trimethylammonium chloride
J-001121
mfcd00145456
dotma, 1,2-di-o-octadecenyl-3-trimethylammonium propane (chloride salt), powder
dotma, 1,2-di-o-octadecenyl-3-trimethylammonium propane (chloride salt), chloroform
LDGWQMRUWMSZIU-LQDDAWAPSA-M
2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride
BS-51321
dotma?
EX-A5047
BP-25706
n,n,n-trimethyl-2,3-bis((z)-octadec-9-en-1-yloxy)propan-1-aminium chloride
CS-0185844
PD088777
E85159
HY-W127644

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"We developed binary and ternary complexes based on polymers and liposomes for safe and effective delivery of small interfering RNA (siRNA)."( Safe and effective delivery of small interfering RNA with polymer- and liposomes-based complexes.
Harauchi, S; Higuchi, N; Ichikawa, N; Kawanabe, S; Kitahara, T; Kodama, Y; Muro, T; Nakagawa, H; Nakamura, T; Sasaki, H, 2013
)
0.39

Compound-Compound Interactions

ExcerptReferenceRelevance
" These data indicate that rejection of primary and metastatic tumors can be achieved after intratumoral delivery of a nonviral IL-2 gene therapy, and is increased in combination with systemic delivery of a conventional chemotherapeutic agent."( Antitumoral effect of a nonviral interleukin-2 gene therapy is enhanced by combination with 5-fluorouracil.
Batten, TL; Bishop, JS; Matar, M; Muller, S; Munger, WE; Pericle, F; Quezada, A; Thull, NM, 2000
)
0.31

Dosage Studied

ExcerptRelevanceReference
" These results indicate that a single dosing of CpG ODN-lipoplex is effective in inhibiting peritoneal dissemination and inducing long-lasting antitumor immunity."( Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex.
Hashida, M; Hyoudou, K; Kuramoto, Y; Nishikawa, M; Yamashita, F, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (97)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (5.15)18.7374
1990's44 (45.36)18.2507
2000's30 (30.93)29.6817
2010's15 (15.46)24.3611
2020's3 (3.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.74 (24.57)
Research Supply Index4.62 (2.92)
Research Growth Index5.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other98 (98.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]